NCT01256853CompletedPhase 1
A Phase I, Dose Escalation Trial of Recombinant Modified Vaccinia Ankara (MVA)-Based Vaccine Encoding Epstein-Barr Virus Target Antigens
Chinese University of Hong Kong1 site in 1 country18 target enrollmentStarted: September 2006Last updated:
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 1
- Status
- Completed
- Enrollment
- 18
- Locations
- 1
- Primary Endpoint
- To determine safety and to characterise the toxicity profile of MVA-EBNA1/LMP2 vaccine
Study Overview
Brief Summary
This is a phase I, dose escalation trial of MVA-EBNA1/LMP2 vaccine across a pre-defined range of doses in patients in remission having had an EBV+ nasopharyngeal carcinoma (NPC).
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Histologically confirmed NPC, in which the presence of EBV within the malignant cells has been demonstrated by (1) EBER (EBV early RNA) in situ hybridisation in more than 50% of the malignant cells, or (2) undifferentiated or poorly differentiated carcinoma histology in association with a raised serum titer of IgA to EBV VCA.
- •Patients in remission from disease, ie complete response (CR) or unconfirmed complete response (CRu).
- •Completion of standard therapy for malignancy at least 12 weeks before trial entry.
- •Written informed consent and the ability of the patient to co-operate with treatment and follow up must be ensured and documented.
- •Age greater than 18 years.
- •World Health Organisation (WHO) performance status of 0 or 1
- •Life expectancy of at least 4 months.
- •Haematological and biochemical indices (these measurements must be performed within 28 days prior to the patient going on study):
- •Haemoglobin (Hb) > 10.0 g/dl
- •Lymphocytes > 1.0 x 109/L (or above the lower limit of normal range of institutional laboratory)
- •Neutrophils ≥ 1.5 x 109/L
- •Platelets (Plts) ≥ 100 x 109/L
- •baseline liver function tests :
- •Serum bilirubin ≤ 1.5 x upper normal limit
- •Serum alkaline phosphatase, alanine amino-transferase (ALT) and/or aspartate amino-transferase (AST) < 1.5 x ULN.
- •baseline renal function test:
- •calculated creatinine clearance > 50ml/min Female patients of child-bearing potential are eligible, provided they have a negative pregnancy test prior to enrolment and agree to use appropriate medically approved contraception during the study up to six months after the last vaccination.
- •Male patients must agree to use appropriate medically approved contraception during the study up to six months after the last vaccination.
Exclusion Criteria
- •Receiving current chemotherapy or radiotherapy, or received within 12 weeks of trial entry.
- •Known chronic active infection with Hepatitis B, Hepatitis C or Human Immunodeficiency Virus (HIV).
- •Current active autoimmune disease.
- •Current active skin diseases requiring therapy (psoriasis, eczema etc).
- •Ongoing active infection.
- •History of anaphylaxis or severe allergy to vaccination.
- •Allergy to eggs or egg products.
- •Previous myeloablative therapy followed by an autologous or allogeneic haematopoietic stem cell transplant.
- •Patients who have had a splenectomy or splenic irradiation, or with known splenic dysfunction.
- •Receiving current immunosuppressive medication, including corticosteroids.
- •Pregnant and lactating women.
- •Ongoing toxic manifestations of previous treatment. Exceptions to this are alopecia or certain Grade 1 toxicities which in the opinion of the Investigator and Cancer Research UK should not exclude the patient.
- •Major thoracic and/or abdominal surgery in the preceding four weeks from which the patient has not yet recovered.
- •Patients with any other condition which in the Investigator's opinion would not make the patient a good candidate for the clinical trial.
- •Concurrent congestive heart failure or prior history of class III/ IV cardiac disease
Arms & Interventions
MVA Vaccine
Experimental
Intervention: MVA Vaccine (Drug)
Outcomes
Primary Outcomes
To determine safety and to characterise the toxicity profile of MVA-EBNA1/LMP2 vaccine
Time Frame: 4 years
Secondary Outcomes
- To describe changes in the frequency of functional T-cell responses to MHC class I and II-restricted epitopes within EBNA1 and LMP2 in peripheral blood at sequential time-points before, during and up to nine months after the vaccination course.(4 years)
- To assess changes in levels of EBV genome levels in plasma(4 Years)
Investigators
CCTU
Comprehensive Clinical Trial Unit
Chinese University of Hong Kong
Study Sites (1)
Loading locations...
Similar Trials
Active, not recruiting
Phase 1
Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) MutationsNon-Small Cell Lung Cancer (NSCLC)Metastatic Non-Small Cell Lung CancerAdvanced Non-Small Cell Lung CancerHER2 Exon 20 MutationsEGFR Exon 20 MutationsEGFR Uncommon Mutations, Including G719X and S768INCT05364073ArriVent BioPharma, Inc.160
Completed
Phase 1
A Clinical Trial to Evaluate the Safety, Efficacy and Immune Responses After Vaccination With an Investigational RNA-based Vaccine Against MalariaMalariaNCT06069544BioNTech SE163
Completed
Phase 1
Phase 1b DV281 With an Anti-PD-1 Inhibitor in NSCLCAdvanced Non Small Cell Lung CancerNCT03326752Dynavax Technologies Corporation26
Recruiting
Phase 1
Effect of NAC on Preventing Chemo-Related Cognitive Impairments in Ovarian Ca Pts Treated W/ PBTOvarian CancerCognitive ImpairmentNCT04520139University of California, Irvine102
Terminated
Phase 1
MSC2015103B in Solid TumorsAdvanced Solid TumorNCT01453387EMD Serono28